Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia

BMC Endocrine Disorders

Carlos A Aguilar-Salinas³  Marja-Riitta Taskinen²  Niina Matikainen²  Päivi Pajukanta⁴  Francisco J Gomez-Perez³  Maria Teresa Tusie-Luna⁵  Oscar Perez-Mendez¹  Ivette Cruz-Bautista³  Liliana Muñoz-Hernandez³  Roopa Mehta³  Daniel Cuevas-Ramos³  Paloma Almeda-Valdes³ 

[1] Department of Molecular Biology. Instituto Nacional de Cardiologia Ignacio A. Chavez, Mexico City, Mexico;Diabetes and Obesity Units, Heart and Lung Center, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland;Department of Endocrinology and Metabolism. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico;Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA;Molecular Biology and Genomic Medicine Units. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Biomedical Investigation Institute, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico

关键词: Waist to hip ratio;    Abdominal obesity;    Apo A-V;    Apo B-48;    Triglycerides;    Postprandial lipemia;   

Others  :  1084768
DOI  :  10.1186/1472-6823-14-90

 received in 2014-05-22, accepted in 2014-11-17,  发布年份 2014

【 摘 要 】

Background

Alterations in postprandial metabolism have been described in familial combined hyperlipidemia (FCH); however, their underlying mechanisms are not well characterized. We aimed to identify factors related to the magnitude of postprandial lipemia and apolipoprotein (apo) A-V levels in subjects with FCH.

Methods

FCH cases (n = 99) were studied using a standardized meal test. Abdominal obesity was assessed using the waist to hip ratio (WHR). A linear regression model was performed to investigate the variables associated with the triglycerides incremental area under the curve (iAUC). Independent associations between metabolic variables and apo A-V iAUC were also investigated in a randomly selected subgroup (n = 44). The study sample was classified according to the presence of fasting hypertriglyceridemia (≥150 mg/dL) and abdominal obesity (WHR ≥0.92 in men and ≥0.85 in women) to explore differences in parameters.

Results

The fasting apo B-48 levels (r = 0.404), and the WHR (r = 0.359) were independent factors contributing to the triglycerides iAUC (r² = 0.29, P < 0.001). The triglycerides iAUC was independently associated with the apo A-V iAUC (r² = 0.54, P < 0.01). Patients with both hypertriglyceridemia and abdominal obesity showed the most robust triglycerides and apo A-V postprandial responses.

Conclusions

In patients with FCH the fasting apo B-48 level is the main factor associated with postprandial lipemia. Abdominal obesity also contributes to the magnitude of the postprandial response.

The triglycerides postprandial increment is the principal factor associated with the apo A-V postprandial response.

【 授权许可】

   
2014 Almeda-Valdes et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Goldberg IJ, Eckel RH, McPherson R: Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol 2011, 31(8):1716-1725.
• [2]Cohn JS, Johnson EJ, Millar JS, Cohn SD, Milne RW, Marcel YL, Russell RM, Schaefer EJ: Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 1993, 34(12):2033-2040.
• [3]Hwu CM, Lin MW, Liou TL, Hsiao LC, Liang KW, Tsai TT, Ho LT: Fasting triglyceride is a major determinant of postprandial triglyceride response in postmenopausal women. Menopause 2008, 15(1):150-156.
• [4]Tan KC, Tso AW, Ma OC, Pang RW, Tam S, Lam KS: Determinants of postprandial triglyceride and remnant-like lipoproteins in type 2 diabetes. Diabetes Metab Res Rev 2005, 21(2):209-214.
• [5]van Wijk JP, Halkes CJ, Erkelens DW, Castro Cabezas M: Fasting and daylong triglycerides in obesity with and without type 2 diabetes. Metab Clin Exp 2003, 52(8):1043-1049.
• [6]Pirro M, Lupattelli G, Siepi D, Palumbo B, Roscini AR, Marchesi S, Schillaci G, Mannarino E: Postprandial lipemia and associated metabolic disturbances in healthy and hyperlipemic postmenopausal women. Metab Clin Exp 2001, 50(3):330-334.
• [7]Sharma V, Forte TM, Ryan RO: Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol. Curr Opin Lipidol 2013, 24(2):153-159.
• [8]van Dijk KW, Rensen PC, Voshol PJ, Havekes LM: The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr Opin Lipidol 2004, 15(3):239-246.
• [9]Aguilar Salinas CA, Zamora M, Gomez-Diaz RA, Mehta R, Gomez Perez FJ, Rull JA: Familial combined hyperlipidemia: controversial aspects of its diagnosis and pathogenesis. Semin Vasc Med 2004, 4(2):203-209.
• [10]Carr MC, Brunzell JD: Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004, 89(6):2601-2607.
• [11]Castro Cabezas M: Postprandial lipaemia in familial combined hyperlipidaemia. Biochem Soc Trans 2003, 31(Pt 5):1090-1093.
• [12]Valles V, Aguilar-Salinas CA, Gomez-Perez FJ, Rojas R, Franco A, Olaiz G, Rull JA, Sepulveda J: Apolipoprotein B and A-I distribution in Mexican urban adults: results of a nationwide survey. Metab Clin Exp 2002, 51(5):560-568.
• [13]del Rincon Jarero JP, Aguilar-Salinas CA, Guillen-Pineda LE, Gomez-Perez FJ, Rull JA: Lack of agreement between the plasma lipid-based criteria and apoprotein B for the diagnosis of familial combined hyperlipidemia in members of familial combined hyperlipidemia kindreds. Metab Clin Exp 2002, 51(2):218-224.
• [14]Mata P, Alonso R, Ruiz Garcia A, Diaz Diaz JL, Gonzalez N, Gijon Conde T, Martinez Faedo C, Moron I, Arranz E, Aguado R, Argueso R, Perez de Isla L: Familial combined hyperlipidemia: consensus document. Atencion Primaria Sociedad Espanola Medicina Familia y Comunitaria 2014, 46(8):440-446.
• [15]Syvanne M, Talmud PJ, Humphries SE, Fisher RM, Rosseneu M, Hilden H, Taskinen MR: Determinants of postprandial lipemia in men with coronary artery disease and low levels of HDL cholesterol. J Lipid Res 1997, 38(7):1463-1472.
• [16]Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18(6):499-502.
• [17]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419.
• [18]Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22(9):1462-1470.
• [19]Maki KC, Kelley KM, Lawless AL, Hubacher RL, Schild AL, Dicklin MR, Rains TM: Validation of insulin sensitivity and secretion indices derived from the liquid meal tolerance test. Diabetes Technol Ther 2011, 13(6):661-666.
• [20]Kolovou GD, Anagnostopoulou KK, Pavlidis AN, Salpea KD, Iraklianou SA, Tsarpalis K, Damaskos DS, Manolis A, Cokkinos DV: Postprandial lipemia in men with metabolic syndrome, hypertensives and healthy subjects. Lipids Health Dis 2005, 4:21. BioMed Central Full Text
• [21]Sharrett AR, Heiss G, Chambless LE, Boerwinkle E, Coady SA, Folsom AR, Patsch W: Metabolic and lifestyle determinants of postprandial lipemia differ from those of fasting triglycerides: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol 2001, 21(2):275-281.
• [22]Guerci B, Verges B, Durlach V, Hadjadj S, Drouin P, Paul JL: Relationship between altered postprandial lipemia and insulin resistance in normolipidemic and normoglucose tolerant obese patients. Int J Obes Relat Metab Disord 2000, 24(4):468-478.
• [23]Meijssen S, Cabezas MC, Twickler TB, Jansen H, Erkelens DW: In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J Lipid Res 2000, 41(7):1096-1102.
• [24]Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001, 294(5540):169-173.
• [25]Kahri J, Fruchart-Najib J, Matikainen N, Fruchart JC, Vakkilainen J, Taskinen MR: The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activity. Diabetes Care 2007, 30(8):2083-2085.
• [26]Ribalta J, Figuera L, Fernandez-Ballart J, Vilella E, Castro Cabezas M, Masana L, Joven J: Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin Chem 2002, 48(9):1597-1600.
• [27]O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, Schultze AE, Konrad RJ: The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 2005, 51(2):351-359.
• [28]Welborn TA, Dhaliwal SS: Preferred clinical measures of central obesity for predicting mortality. Eur J Clin Nutr 2007, 61(12):1373-1379.